...The once-weekly injection of minute amounts of Gc-MAF, just 100 nanograms (billionths of a gram), activates macrophages and allows the immune system to pursue cancer cells with vigor, sufficient to produce total long-term cures in humans..."

"...Normal Gc protein (also called Vitamin-D binding protein) , an abundant glyco-protein found in human blood serum, becomes the molecular switch to activate macrophages when it is converted to its active form, called Gc macrophage activating factor (Gc-MAF). Gc protein is normally activated by conversion to Gc-MAF with the help of the B and T cells (bone marrow-made and thymus gland-made white blood cells). But, as researchers explain it themselves, cancer cells secrete an enzyme known as alpha-N-acetylgalactosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to Gc-MAF, preventing tumor-cell killing by the macrophages. This is the way cancer cells escape detection and destruction, by disengaging the human immune system. This also leaves cancer patients prone to infections and many then succumb to pneumonia or other infections...

October 2008, Bill Sardi and Timothy Hubbell  in their piece "Cancer Cured for Good" wrote about the Gc-maf cancer therapy of Dr. Yamamoto.

First I had to agree with those who affirm that Yamamoto'sresearch is rather weak, because his studies have enroled very few patients, research design is quite original and the monitoring of tumor growth is not performed through normal measures and references in Yamamoto's bibliographies are often oriented to his own research.

However, I had to concede that if even just a small part of Yamamoto claims are true, still we would be in need of very serious research on this Gc-maf molecule.

I tried to dig some more into this subject and found that other authors had already shown clear anticancer effectiveness of Gc-maf, they called it DBP-maf.

One paper in particular: "Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice." Neoplasia. 2003 Jan-Feb;5(1):32-40, among others, brought the signature of J. Folkman, a scientist who everybody would probably have heard of and, already a nobel prize, was not in need of more fame or glory.

So I do not understand how, after such results as those presented in that paper, so few scientists have followedthe track.

And I had to admint that, for the usual stubborness of mainstream research, we are today still stuch with Dr. Yamamoto rather weak model alone, when we could have already gathered much more insight into his terrific discovery.

A few other groups around the world have also questioned Yamamoto model quite effectively, even if nobody has yet disproved the immunostimulatory and antiangiogenic potential of the Gc-maf (DBP-maf) protein.

In conclusion, I just would like to see some new paper on this topic and possibly even some clinical trial recruiting, which would provide sufferers with an opportunity and new hope.